Consensus ResMed, Inc.

Equities

RMD

US7611521078

Real-time Estimate Cboe BZX Other stock markets 02:07:33 2024-04-26 pm EDT			5-day change	1st Jan Change
216 ^USD	+17.76%		+21.21%	+26.03%

07:54pm	Sector Update: Health Care Stocks Higher in Afternoon Trading	MT
07:35pm	In-Line Inflation Data, Tech Earnings Lift US Equity Indexes	MT

Evolution of the average Target Price on ResMed, Inc.

Price target over the last 5 years

History of analyst recommendation changes

592a8ff705ec69b.DkuWyUI70R1i6c-ibWE7f-6JTYQdHDRFl3exfBeGCgg.WiXGgAoDpXtSnIbTIQAJLZe_C9NlcncmuiXBSl3kQGk_E_GPB1jkWBuDpA~f2028d308dda21288dbb999b6ce18228

Analyst Recommendations on ResMed, Inc.

KeyBanc Adjusts Price Target on ResMed to $238 From $227	11:37am	MT
Jefferies Adjusts Price Target on ResMed to $180 From $164	10:36am	MT
Oppenheimer Adjusts ResMed Price Target to $200 From $205, Maintains Outperform Rating	09:09am	MT
JPMorgan Adjusts Price Target on ResMed to $225 From $198	09:00am	MT
Mizuho Adjusts Price Target on ResMed to $220 From $215	08:09am	MT
Needham Adjusts Price Target on ResMed to $236 From $224	08:01am	MT
Morgan Stanley Adjusts Price Target on ResMed to $219 From $207	06:40am	MT
RBC Adjusts Price Target on ResMed to $200 From $187	06:18am	MT
Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	Apr. 01	MT
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight	Mar. 05	MT
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target is AU$31	Mar. 04	MT
Powell, the paper tiger	Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
Mizuho Adjusts Price Target on ResMed to $215 From $195, Keeps Buy Rating	Jan. 30	MT
Oppenheimer Raises ResMed Price Target to $205 From $185, Maintains Outperform Rating	Jan. 30	MT
UBS Adjusts ResMed Price Target to $180 From $175, Maintains Neutral Rating	Jan. 25	MT
Oppenheimer Raises ResMed Price Target to $185 From $175, Maintains Outperform Rating	Jan. 25	MT
RBC Lifts Price Target on ResMed to $182 From $181, Cites 'Solid' Fiscal Q2 Results, Keeps Sector Perform Rating	Jan. 25	MT
RBC Cuts Price Target on ResMed to $181 From $200, Keeps Sector Perform Rating	Jan. 22	MT
JPMorgan Adjusts Price Target on ResMed to $195 From $160, Maintains Overweight Rating	Jan. 09	MT
Nvidia comes to Wall Street's rescue	Jan. 09
ANALYST RECOMMENDATIONS : Blackrock, Blackstone, Exxon Mobil, Netflix, Charles Schwab...	Jan. 09
Joe Biden and Xi Jinping almost made up	Nov. 16
ANALYST RECOMMENDATIONS : Abbvie, Burberry, Chevron, Cisco, M&S...	Nov. 16
North American Morning Briefing : Rate Decisions, -2-	23-10-30	DJ

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

183.4 USD

Average target price

208.6 USD

Spread / Average Target

+13.72%

High Price Target

258 USD

Spread / Highest target

+40.66%

Low Price Target

180 USD

Spread / Lowest Target

-1.86%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ResMed, Inc.

Needham & Co.
Morgan Stanley
Evans & Partners
Mizuho Securities
Oppenheimer
UBS
RBC Capital Markets
JPMorgan Chase
BofA Securities
Wolfe Research
KeyBanc Capital Markets
JMP Securities
Jefferies & Co.
Citigroup
Goldman Sachs
Baird
Macquarie
J.P. Morgan Chase

Ratings for ResMed, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar